Pregnancy & Ferility

A CDC report finds that pregnant women with COVID-19 at delivery face a nearly 2X risk of stillbirth, and a 4X risk from the Delta variant.

Pregnant women with COVID-19 are more likely to be admitted to the intensive care unit and their babies born prematurely. Clinical trials excluded pre…

SMFM recommends COVID-19 vaccination during pregnancy to reduce risks and protect mothers and infants. Safe, effective, and supported by data.

COVID-19 vaccination has been shown to be safe in pregnancy, and protects both the mother and infant from severe disease. It’s now also clear that infants’ antibody protection continues after birth.

Let's break down some notable differences between Moderna and Pfizer

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

Recipients of jab while pregnant recall confusing advice and ‘vicious’ social media comments

Researchers suggest this provides further evidence of benefit of SARS-CoV-2 vaccination before or during pregnancy.

Dangerous rumors have been swirling on social media that getting vaccinated against the coronavirus could hamper male and female fertility.

Pregnant people experienced lower rates of side-effects from the COVID-19 vaccine than their counterparts who weren't pregnant, a new Canadian study suggests.

Existing evidence on the safety and efficacy of getting a COVID vaccine in pregnancy all points the same way: the shot is important for maternal and fetal health.

Rare serious complications have been documented after COVID-19 vaccination as clinical research proceeded and new target populations, such as children and ‎pregnant women, were included. In this study, we attempted to review the literature relevant ...

Pregnant people with COVID-19 are at increased risk of severe illness and death compared with non-pregnant females of reproductive age (aged 15–49 years).1 Additionally, COVID-19 during pregnancy is associated with increased risk for adverse pregnancy outcomes, such as preterm birth and stillbirth.1 When mRNA COVID-19 vaccines first became available in December, 2020, safety data in pregnancy were limited because pregnant people were excluded from pre-authorisation clinical trials.2 Lack of data and safety concerns contributed to initially low uptake among pregnant people, which continues to be lower than uptake among non-pregnant females of reproductive age.

Recent research provides evidence to back the safety and effectiveness of the COVID-19 vaccine for pregnant women.

TORONTO - Canada's gynecologists say COVID-19 vaccination "remains safe and strongly recommended" during pregnancy and while breastfeeding.

Since first being identified in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an etiological agent behind Coronavirus disease 19 (COVID-19), has caused three waves of a global pandemic, with a fourth in progress. ...

Canadian data suggests people who are pregnant face significantly higher risks of serious COVID-19 requiring hospitalization, ICU admission, or life support — a particular concern because pregnant people tend to have lower rates of vaccination.

Objectives This study aimed to investigate the impact of pregnancy and pre-existing comorbidities on COVID-19 infections and associated complications of hospitalisation and mortality in women of reproductive age (WRA). The study also compared the risk of severe COVID-19 complications between pregnant women (PW) and non-pregnant women (NPW) with and without pre-existing comorbidities. Special focus was placed on some understudied comorbidities of immunosuppression, chronic renal disease and chronic obstructive pulmonary disease (COPD). Methods The study utilized anonymized patient-related information for a population of 7,342,869 WRA from the Mexican Ministry of Health data repository on COVID-19. Descriptive variables were characterized using frequencies, percentages, means, and standard deviations. Adjusted odds ratios (aORs) were used to assess the associations between risk factors and outcomes of hospitalisation and mortality. The study covered the entire COVID-19 pandemic period from January 30, 2020, to May 5, 2023. Results The findings revealed that PW were not more likely to get COVID-19 infections than NPW. PW with COVID-19 infections were more likely to require hospital admission, intubation treatments, and ICU admission compared to NPW with COVID-19. PW with immunosuppression had an increased odds ratio (aOR) of getting COVID-19 infections compared to NPW (PW: aOR = 1.0396; NPW: aOR = 0.8373). NPW with immunosuppression had higher risk of mortality (all-cause death: aOR = 1.7084; COVID-19-associated death: aOR = 1.4079) and hospitalisation (all-cause hospitalisation: aOR = 4.1328; COVID-19-associated hospitalisation: aOR = 3.0451) than NPW without immunosuppression. Renal disease was identified as a concerning pre-existing condition that increased the risks of COVID-19 associated mortality/hospitalizations and all-cause mortality/hospitalizations for both PW and NPW. NPW with renal disease had much higher odds ratio (aOR) of either COVID-19-associated-hospitalisations (NPW: aOR = 8.639; PW: aOR = 1.7603) or all-cause hospitalisations (NPW: aOR = 8.8594; PW: aOR = 1.786) than PW with renal disease. Conclusions This study provides valuable insights into the impact of pregnancy and pre-existing comorbidities on COVID-19 outcomes in WRA. The findings underscore the importance of considering demographic factors and pre-existing comorbidities in the management of PW with COVID-19. The study also highlights the need for further research to understand the unique impacts of different comorbidities, particularly immunosuppression and renal disease, on COVID-19 outcomes in WRA.

A new analysis from Oxford Population Health has found that pregnant women that are 30 years old or more, overweight, of mixed ethnicity or have gestational diabetes have a greater risk of